The Regulatory Affairs Professionals Society (RAPS) is stepping up its presence in Europe and expanding its European team in response to growing membership demand from those involved with the regulation of healthcare and related products. In the last 12 months, the largest global organization for regulatory professionals in the healthcare, medical device, biologic and pharmaceutical sectors has reportedly seen its European member base grow by approximately 19 per cent to more than 1,500 members across 29 countries. RAPS plans to invest more than €2 million over three years implementing a strategic growth plan in Europe that includes launching new events and resources to serve the needs of regulatory professionals in the region. The investment program includes a substantial increase in staff resources for European members and a series of European events including a RAPS Roadshow: ‘Examining the New European Medical Device Regulations’ on 4 May in Munich and a workshop ‘EU Regulatory Essentials, Medical Device and In Vitro Diagnostics: Transitioning from Current Directives to New Regulations’ on July 4-5 in Brussels.
FDA Grants Priority Review to GSK’s Gepotidacin for Uncomplicated Urinary Tract Infections
October 18th 2024Priority Review status for GSK’s New Drug Application for gepotidacin was based on promising results from the Phase III EAGLE-2 and EAGLE-3 trials, which demonstrated non-inferiority to nitrofurantoin in uncomplicated urinary tract infections.
FDA Approves Expanded Indication for Lumryz in Pediatric Patients with Narcolepsy
October 18th 2024Expanded approval of Lumryz offers a once-nightly treatment option for younger patients, eliminating the need for traditional narcolepsy treatments that often require multiple doses throughout the night.